Clinical Trials Browser

INDUSTRY × vorasidenib × CNS × Clear all

NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Phase 1 Active not recruiting

Astrocytoma, Oligodendroglioma

NCT07240662 2026-01-09

VIOLETA

Glioma

NCT06969352 2025-05-13

VICTORIA

Not yet recruiting

Glioma

NCT04164901 2025-04-03

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Phase 3 Active not recruiting

331 enrolled 25 charts 1 FDA

Glioma

NCT05592743 2024-11-05

Vorasidenib Expanded Access Program

Approved for marketing

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes